Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0070663 |
| Name | soft tissue sarcoma |
| Definition | A connective tissue cancer that has_material_basis_in abnormally proliferating cells derived from embryonic mesoderm and starts in the soft tissues of the body (e.g. fat, muscle, nerves, blood vessels). |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer soft tissue sarcoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| RET fusion | Selpercatinib | soft tissue sarcoma | sensitive | detail... |
| MLH1 negative | Pembrolizumab | soft tissue sarcoma | sensitive | detail... |
| MSH6 negative | Pembrolizumab | soft tissue sarcoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03138161 | Phase Ib/II | Ipilimumab + Nivolumab + Trabectedin | Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
| NCT03242382 | Phase II | Palbociclib | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) | Recruiting | ESP | 0 |
| NCT03784014 | Phase III | Ceritinib Dabrafenib + Trametinib Capmatinib Durvalumab + Olaparib Nilotinib Futibatinib Trametinib Palbociclib Glasdegib Lapatinib | Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC) | Active, not recruiting | FRA | 0 |
| NCT04095208 | Phase II | Nivolumab + Relatlimab Nivolumab | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (CONGRATS) | Active, not recruiting | FRA | 0 |
| NCT04595994 | Phase I | Gemcitabine + Selinexor | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma (SeliSarc) | Recruiting | ESP | 0 |
| NCT04650984 | Phase III | Doxorubicin + Onfekafusp alfa Doxorubicin | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC) | Recruiting | POL | ITA | FRA | ESP | DEU | 0 |
| NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Active, not recruiting | ESP | 0 |
| NCT06239272 | Phase Ib/II | Selinexor Pazopanib Doxorubicin + Ifosfamide | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | Recruiting | USA | 0 |
| NCT06474676 | Phase I | AttIL12 T-cells Cyclophosphamide | T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. | Recruiting | USA | 0 |
| NCT06797999 | Phase Ib/II | ADCE-D01 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (ADCElerate1) | Recruiting | USA | GBR | FRA | DEU | BEL | 0 |